Search for content, post, videos

Immunovia expands to a new type of cancer

Mats Grahn

In a new collaborative study with a major global pharma company, Immunovia’s blood-based testing platform, IMMray could differentiate healthy controls from non-small cell lung cancer (NSCLC) samples with a 95 % accuracy, reports the company.

The study included 100 serum samples – 50 NSCLC and 50 controls – and was performed to assess the technical performance of the IMMray platform in lung cancer. As a consequence of the encouraging high diagnostic accuracy of 95% obtained with IMMray during this project, the parties now plan for continued collaboration by adding larger studies to confirm these preliminary findings.

“Since IMMray has previously demonstrated similar high (98%) accuracy in detecting pancreatic cancer, the results from this study strengthen our belief that IMMray has the potential to become a standard common platform for cancer diagnosis based on blood samples, and we are very much looking forward to the next steps of this collaboration”, CEO Mats Grahn said in a statement.